Drugs Begining With“e”
Investigated for use/treatment in alzheimer's disease.
Investigated for use/treatment in breast cancer, cancer/tumors (unspecified), head and neck cancer, lung cancer, prostate cancer, and sarcoma.
Investigated for use/treatment in solid tumors.
For the treatment of reflux oesophagitis and peptic ulcer disease.
For the treatment of angioedema.
For use in the treatment of subacute or chronic angle-closure glaucoma after iridectomy or where surgery is refused or contraindicated.
Investigated for use/treatment in cancer/tumors (unspecified).
For topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor.
For the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
Investigated for use/treatment in osteoporosis.
For the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant treatment. It was in phase III clinical trials, in 2012, for major depressive disorder, but failed to get approval.